Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

New prediction model can identify NSCLC patients who are not likely to respond to immunotherapy

Immunotherapy agents that inhibit the molecules PD1, PD-L1 or CTLA-4 have become widely used in clinical practice to treat non-small cell lung cancer, or NSCLC.

20 Aug 2021

MD Anderson receives nearly $13 million from CPRIT to support research efforts

The University of Texas MD Anderson Cancer Center has been awarded $12.75 million from the Cancer Prevention and Research Institute of Texas to support basic, clinical, translational and prevention research efforts, including $3 million for a new project to build clinical trial network infrastructure across Texas.

19 Aug 2021

New assay using fresh uncultured lung tumor cells could guide personalized treatments

A new study from the University of Helsinki shows that cells that are freshly isolated from lung cancers can be used to create robust drug response data. This approach can identify actionable or non-responsive treatments, illustrated by a case study in which the assay was used to guide the compassionate treatment of a patient.

18 Aug 2021

Yale perspective highlights new breakthrough therapies to treat non-small cell lung cancer

A new publication by Yale Cancer Center highlights recent breakthrough therapies developed to treat non-small cell lung cancer (NSCLC).

12 Aug 2021

New approach could be a useful tool in the fight against cancer drug resistance

Using a virus to purposely mutate genes that produce cancer-driving proteins could shed light on the resistance that inevitably develops to cancer drugs that target them, a new study led by UT Southwestern scientists suggests.

10 Aug 2021

Study may provide a new therapeutic target for treatment of LUAD patients

Aging-US published "A novel ferroptosis-related gene signature for prognostic prediction of patients with lung adenocarcinoma" which reported that RNA-seq transcriptome data of LUAD patients were obtained from The Cancer Genome Atlas database.

9 Aug 2021

Experimental drug combination extends survival in mice with lung cancer, study finds

A combination of experimental drugs increased the attack of immune cells on non-small cell lung cancer (NSCLC) to extend survival in mice, a new study found.

5 Aug 2021

MET amplification identified as a potentially actionable driver for non-small cell lung cancer

A study led by D. Ross Camidge, MD, PhD, director of thoracic oncology at the University of Colorado School of Medicine and CU Cancer Center member, has helped to define MET amplification as a rare but potentially actionable driver for non-small cell lung cancer (NSCLC).

20 Jul 2021

IR imaging-based AI offers a label-free and automated approach to identify lung tumor types

Infrared spectroscopy can automatically distinguish between various types of lung cancer and genetic mutations, allowing quick and reliable statements to be made regarding prognosis and treatment decisions.

28 Jun 2021

Moffitt awarded $10.2 million grant to investigate lung cancer metabolism

The National Cancer Institute has awarded the Lung Cancer Metabolism Working Group at Moffitt Cancer Center with a Research Program Project Grant (P01CA250984).

28 Jun 2021

Study highlights the impact of structural racism and residential segregation on lung cancer outcomes

Lung cancer remains the leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for 80-85 percent cases of lung cancer and when diagnosed early, has a five-year survival rate of 50-80 percent.

22 Jun 2021

Study uncovers new mechanisms underlying lineage plasticity

Cancer cells have an uncanny ability to evolve and adapt to overcome the treatments used against them. While patient survival has been extended by modern drugs that block the production or action of male hormones that fuel prostate cancer -- androgen receptor inhibitors such as enzalutamide, apalutamide, darolutamide, and abiraterone -- eventually these drugs stop working.

21 Jun 2021

PET/CT images can be used to measure biomarker levels, predict lung cancer outcomes

Tests that analyze biomarkers are used during cancer management to guide treatment and provide information about patient prognosis.

17 Jun 2021

Study uncovers novel drug that effectively thwarts pancreatic tumors

Pancreatic cancer is an aggressive disease in which malignant cells form in the tissues of the pancreas, a long and flat gland located behind the stomach that helps with digestion and blood sugar regulation.

14 Jun 2021

Study: Lung squamous patients harboring druggable mutations have lower median overall survival

Oncotarget published "Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations" which reported that unlike lung adenocarcinoma patients, there is no FDA-approved targeted-therapy likely to benefit lung squamous cell carcinoma patients.

3 Jun 2021

SWOG researchers to present practice-changing research at virtual ASCO 2021

"SWOG always brings an impressive portfolio of work to the ASCO annual meeting," said SWOG Chair Charles D. Blanke, MD, "and this year I'm particularly excited about the research our investigators are presenting because it includes results that are likely to be practice-changing."

1 Jun 2021

FDA approves targeted therapy for tumors with KRAS mutations

Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy.

29 May 2021

FDA approves Rybrevant for treating subset of non-small cell lung cancer

Today, the U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

21 May 2021

New approach combines molecular and medical imaging data to diagnose cancer type

Despite our remarkable advances in medicine and healthcare, the cure to cancer continues to elude us. On the bright side, we have made considerable progress in detecting several cancers in earlier stages, allowing doctors to provide treatments that increase long-term survival.

11 May 2021

Study identifies novel combination therapy to help patients with advanced lung cancer

A new study by researchers at the UCLA Jonsson Comprehensive Cancer Center has identified a novel combination therapy to potentially help overcome resistance to immunotherapy in people diagnosed with advanced lung cancer.

5 May 2021